Secondary mutations inducing genetic resistance as seen in BCR-ABL driven malignancies exposed to BCR-ABL inhibitors occur upon exposure to JAK2 inhibitors in vitro, but have not been observed in MPN patients [93,94]. Here, JAK2 is linked to myeloproliferative disorder.